Screener
Ginkgo Bioworks DNA CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchases of marketable debt securities | (127,445) | (320,132) |
| Maturities of marketable debt securities | 166,168 | 64,958 |
| Purchases of property and equipment | (4,552) | (7,660) |
| Other | 48 | 262 |
| Net cash provided by (used in) investing activities | 34,219 | (262,572) |
| Cash flows from financing activities: | ||
| Proceeds from ATM offering | 17,049 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's capex?
- Ginkgo Bioworks (DNA) reported capex of $2.62M in Q2 2026.
- How has Ginkgo Bioworks's capex changed year-over-year?
- Ginkgo Bioworks's capex increased by 6792.1% year-over-year, from $38K to $2.62M.
- What is the long-term trend for Ginkgo Bioworks's capex?
- Over 4 years (2021 to 2025), Ginkgo Bioworks's capex has grown at a -39.3% compound annual growth rate (CAGR), from $56.52M to $7.67M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Ginkgo Bioworks's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude